ArticleFrontiers in endocrinology2025
Elevated total cholesterol in healthy adults mediates the association between impaired thyroid hormone sensitivity and hyperuricemia.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between impaired peripheral thyroid hormone sensitivity and coronary heart disease in type 2 diabetes: the potential mediating role of albumin.Frontiers in endocrinology · 2026Article
- Traditional Chinese Medicine in Hyperuricemia: Current Advances, Mechanistic Insights, and Clinical Challenges.International journal of general medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aims to explore the association between impaired thyroid hormone sensitivity and hyperuricemia, and to analyze the potential mediating role of total cholesterol (TC), thereby providing a new theoretical basis for the early prevention and intervention of hyperuricemia. Methods: This study utilized health check-up data from Health Examination Management Center of the second affiliated hospital of Zhejiang University School of Medicine, collected between 2019 and 2020. The dataset included 80568 participants with normal thyroid function, no family history of thyroid disorder, and no history of thyroid hormone or lipid-lowering medication use. The extent of impaired thyroid hormone sensitivity was assessed using thyroid hormone sensitivity indices, such as the Thyroid Feedback Quantile Index (TFQI), Parameter Thyroid Feedback Quantile Index (PTFQI), Thyroid Resistance Index (TT4RI), and Thyroid Stimulating Hormone Index (TSHI). Logistic regression models were employed to analyze the relationship between thyroid hormone sensitivity indices and hyperuricemia, while mediation analysis was conducted to quantify the mediating effect of total cholesterol. Result: Among the 22843 participants, 6597(28.88%) were diagnosed with hyperuricemia. The thyroid hormone sensitivity indices (TFQI, PTFQI, TT4RI, and TSHI) were notably elevated in the hyperuricemia group compared to the non-hyperuricemia group (P<0.001). A dose-response relationship was observed between thyroid hormone sensitivity indices and hyperuricemia, and this association remained noticeable after adjusting for factors such as age, gender, BMI, hypertension, and diabetes. Mediation analysis indicated that total cholesterol significantly mediated the association between impaired thyroid hormone sensitivity and hyperuricemia, with a mediation proportion ranging from6.89% to 18.42%. Conclusion: This study is the first to uncover a new relevance by which impaired thyroid hormone sensitivity mediates hyperuricemia through total cholesterol. This finding provides fresh epidemiological evidence for the interplay between thyroid dysfunction and hyperuricemia and suggests that monitoring thyroid hormone sensitivity indices in high-risk populations for hyperuricemia might be conducive in early risk stratification. Moreover, lipid-lowering treatment in subclinical thyroid dysfunction patients may simultaneously enhance uric acid metabolism, offering creative insights for the precise prevention and management of hyperuricemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.